报价延迟最少15分钟:2026/11/04 15:48 EST
盘后时段
|
||||
|
-- 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.8656
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.37/-3.00
|
|
企业价值
13.98M
|
| 资产负债 |
|
每股账面净值
1.10
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.77M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. It develops and commercializes radiopharmaceutical platforms for therapeutic and diagnostic applications in precision oncology. The Company develops targeted and scientifically validated radiopharmaceutical technologies in pre-clinical and clinical stages. It has one reportable segment, being the research, development, and commercialization of health technologies. The Company operates in Australia and the United States, with maximum revenue from the United States. |
